Cardiology Online - International Academy of Cardiology
»search site
The International Academy of Cardiology is dedicated to the advancement of global research in cardiovascular medicine through the support of scientific meetings and publications.
   Home Page
   Discussion Groups
   Job Opportunities
   Contact Us





19th World Congress on Heart Disease



Jamshid Shirani, M.D., St. Luke's Hospital and Health Network, Bethlehem, PA, USA


Angiotensin II (AII), an octapeptide member of the renin-angiotensin system (RAS), is formed by the enzyme angiotensin converting enzyme (ACE) and exerts adverse cellular effects through an interaction with its type 1 receptor (AT1R). Both ACE inhibitors and angiotensin receptor blockers (ARB) mitigate the vasoconstrictive, proliferative, proinflammatory, proapototic and profibrotic effects of AII and are widely used as effective antiremodeling agents in clinical practice. Prediction of individual response to these agents, however, remains problematic and is influenced by many factors including race, gender and genotype. In addition, systemic and tissue RAS activity do not correlate closely. Non-invasive determination of tissue ACE activity and AT1R expression using novel nuclear tracers may improve treatment of heart failure through more selective pharmacologic intervention and better dose titration of available drugs while avoiding unnecessary drug toxicity and side effects. Such imaging techniques would also be another step forward in attempts towards personalized approaches to management of advanced heart disease.



©1998-2015 Cardiology Online, Inc. All rights reserved.
Cardiology Online is a registered trademark of Cardiology Online, Inc.